{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline&page=2",
    "query": {
      "intervention": "Saline",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Saline&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T05:14:01.286Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02123615",
      "title": "ASIS for GAMMAGARD in Primary Immunodeficiency",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Gadolinium For abdomen",
          "type": "DRUG"
        },
        {
          "name": "Gadolinium For lower back",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subcutaneously at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subcutaneously at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subcutaneously at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subdermally at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subdermally at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Gammagard subdermally at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subcutaneously at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subcutaneously at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subcutaneously at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subdermally at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subdermally at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Gammagard subdermally at Week 36",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ASIS Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2016-01",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-24",
      "last_synced_at": "2026-09-24T05:14:01.286Z",
      "location_count": 1,
      "location_summary": "Westminster, California",
      "locations": [
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02123615"
    },
    {
      "nct_id": "NCT04141150",
      "title": "Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Mild Cognitive Impairment Due to Alzheimer's Disease",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "[18F]APN-1607",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "APRINOIA Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 130,
      "start_date": "2022-03-22",
      "completion_date": "2025-02",
      "has_results": false,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-09-24T05:14:01.286Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Mount Arlington, New Jersey • New York, New York",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Mount Arlington",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04141150"
    },
    {
      "nct_id": "NCT01258608",
      "title": "Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "Mapatumumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Human Genome Sciences Inc., a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2011-02-08",
      "completion_date": "2017-11-29",
      "has_results": true,
      "last_update_posted_date": "2018-12-19",
      "last_synced_at": "2026-09-24T05:14:01.286Z",
      "location_count": 9,
      "location_summary": "Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Tupelo",
          "state": "Mississippi"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01258608"
    },
    {
      "nct_id": "NCT01923389",
      "title": "Multiple Dose Study Of PF-05231023 In Obese Adult Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus (T2DM)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "100 mg PF-05231023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 4,
      "start_date": "2013-09",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2014-09-17",
      "last_synced_at": "2026-09-24T05:14:01.286Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01923389"
    },
    {
      "nct_id": "NCT02684968",
      "title": "Effects of Continuous Bilateral QL Analgesia After Open Abdominal Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Colorectal surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-03",
      "completion_date": "2019-10",
      "has_results": false,
      "last_update_posted_date": "2021-02-09",
      "last_synced_at": "2026-09-24T05:14:01.286Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02684968"
    },
    {
      "nct_id": "NCT01943240",
      "title": "Pectoral Nerve Blockade in Mastectomy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postoperative Pain",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels",
          "type": "DRUG"
        },
        {
          "name": "10 cc of 0.375% ropivacaine pectoral nerve block",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Timothy R Petersen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-03",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2016-10-27",
      "last_synced_at": "2026-09-24T05:14:01.286Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01943240"
    },
    {
      "nct_id": "NCT07700368",
      "title": "Effect of Monosodium Glutamate on Microbiome-Derived Imidazole Propionate Production in Healthy Volunteers",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Adult"
      ],
      "interventions": [
        {
          "name": "L-histidine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Monosodium glutamate (MSG)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Sodium chloride (NaCl)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2026-07-15",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-09-24T05:14:01.286Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07700368"
    },
    {
      "nct_id": "NCT01740817",
      "title": "A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Intralipid 20%",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2008-01",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2016-01-25",
      "last_synced_at": "2026-09-24T05:14:01.286Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01740817"
    },
    {
      "nct_id": "NCT01335789",
      "title": "Effect of Oxytocin on Stress in Marijuana Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Marijuana Dependence"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2011-03",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2015-12-14",
      "last_synced_at": "2026-09-24T05:14:01.286Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01335789"
    },
    {
      "nct_id": "NCT04160091",
      "title": "Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of the Shoulder",
        "Adhesive Capsulitis"
      ],
      "interventions": [
        {
          "name": "FX006",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 19,
      "start_date": "2019-11-07",
      "completion_date": "2020-06-15",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-09-24T05:14:01.286Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04160091"
    }
  ]
}